GLP-1 Explained: How It Influences Hunger, Weight And Metabolic Health

GLP-1 Explained: How It Influences Hunger, Weight And Metabolic Health

Reported By :

,

Last Updated: June 25, 2026, 10:55 IST

Dr. Mayur Agrawal explains how GLP-1 regulates appetite, satiety and metabolism, and why GLP-1 therapies are transforming obesity and diabetes care.

How GLP-1 regulates appetite, satiety and metabolic health: The Science Behind Modern Obesity Treatment

India is at a pivotal crossroads in its healthcare journey when it comes to tackling obesity and metabolic diseases.

For decades, the country’s healthcare landscape has been dominated by the growing burden of non-communicable diseases (NCDs) such as cardiovascular disease, diabetes and cancer. These chronic illnesses continue to strain public health systems and remain among the leading causes of morbidity and mortality. In recent years, however, a new concern has rapidly intensified this challenge: obesity.

Once considered a condition largely confined to affluent populations, obesity is now rising sharply across socioeconomic groups. Estimates suggest that more than 180 million Indian adults were living with overweight or obesity in 2021, a figure projected to increase to nearly 450 million by 2050. This alarming rise is accelerating the nation’s existing NCD burden.

Dr Mayur Agrawal, Hormone India Clinic, Bhopal feels this growing epidemic is closely linked to type 2 diabetes, cardiovascular disease and several other metabolic complications, making obesity care not only a clinical priority but also a public health imperative. In this context, understanding the science of appetite regulation and metabolism is essential for enabling more precise, mechanism-based treatment strategies.

GLP-1: A Bridge Between the Gut and the Brain

The brain is in constant communication with the digestive system, which does far more than simply process food. The gut releases several hormones that continuously send signals to the brain about hunger, satiety and energy balance.

Among these hormones, glucagon-like peptide-1 (GLP-1) plays one of the most important roles.

When food enters the digestive tract, GLP-1 is released and sends signals to the brain, particularly the hypothalamus, the region responsible for regulating appetite and metabolism. These signals help the body recognise when it has consumed enough food, reducing appetite while increasing feelings of fullness.

At the same time, GLP-1 slows gastric emptying, delaying the movement of food through the gastrointestinal (GI) tract. This prolongs satiety after meals and helps reduce overall food intake.

“GLP-1 acts as a biological messenger between the gut and the brain, helping the body recognise when it has eaten enough," explains Dr Agrawal.

How GLP-1 Influences Eating Behaviour

One of the most clinically significant effects of GLP-1 receptor agonists, such as semaglutide, is their ability to influence eating behaviour.

Obesity is far more than excess body weight. It is often accompanied by persistent hunger, cravings, reward-driven eating and recurring challenges in maintaining a calorie-controlled diet.

Dr Agrawal explains that many patients describe experiencing constant thoughts about food or persistent cravings, often referred to as “food noise." GLP-1-based therapies help reduce this by acting on the brain’s reward pathways while also slowing gastric emptying. As a result, patients often consume fewer calories in a way that feels biologically supported rather than relying solely on willpower.

Central Nervous System Actions

GLP-1 exerts significant effects on the brain, particularly the hypothalamic centres responsible for regulating appetite, metabolism and energy balance. By activating receptors in these regions, it influences neural pathways involved in hunger, satiety, reward-driven eating and glucose homeostasis.

According to Dr Agrawal, this is one of the reasons obesity should be viewed as a chronic disease rather than simply a lifestyle issue. While diet and physical activity remain important, obesity is also driven by complex neurobiological mechanisms that encourage food-seeking behaviour and defend body weight.

GLP-1 receptor agonists directly target these pathways, reducing hunger while promoting healthier metabolic signalling. Their benefits therefore extend beyond symptom control, addressing the biological mechanisms that regulate appetite and energy balance.

Metabolic Benefits of GLP-1

The benefits of GLP-1 extend well beyond appetite regulation and eating behaviour. Its metabolic effects are broad and clinically significant.

Improved Glycaemic Control: GLP-1 enhances glucose-dependent insulin secretion from the pancreas while suppressing glucagon, the hormone that signals the liver to produce glucose. This helps improve blood sugar control in people with type 2 diabetes.

Clinically Meaningful Weight Loss: The Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial programme demonstrated sustained and clinically meaningful weight loss in adults with overweight or obesity. Across these studies, participants achieved an average weight reduction of approximately 10–15%, depending on the study population and treatment duration.

Cardiovascular Benefits: Clinical studies have shown that GLP-1 receptor agonists are associated with improvements in major adverse cardiovascular events (3-point MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. They have also been linked to improved endothelial function and modest reductions in blood pressure.

Improved Lipid Profile: GLP-1 therapies help lower triglyceride levels and LDL (“bad") cholesterol, contributing to better cardiovascular health.

Liver Health: They reduce liver fat and may improve metabolic dysfunction-associated steatotic liver disease (MASLD).

Renal Protection: Studies have also demonstrated kidney-protective effects, often alongside cardiovascular improvements.

Supporting Long-Term Weight Management

Dr Agrawal emphasises that medication alone is not enough for sustainable weight management.

“Long-term success depends on combining GLP-1 therapy with a calorie-controlled diet, regular physical activity and structured behavioural support," he says.

This is particularly important because obesity is a chronic, relapsing disease, where preventing weight regain is often just as important as achieving initial weight loss.

Simple lifestyle measures can further improve outcomes. Prioritising adequate protein intake, maintaining proper hydration, proactively managing gastrointestinal side effects and, where appropriate, considering maintenance dosing can help preserve muscle mass while supporting long-term adherence to treatment.

When used as part of a comprehensive obesity management programme, GLP-1 receptor agonists have the potential to deliver sustained improvements in metabolic health and quality of life.

“GLP-1-based therapies represent a major advance in obesity management, but they work best when integrated into a comprehensive lifestyle programme," concludes Dr Agrawal.

“Understanding how these medicines influence appetite, metabolism and energy regulation enables both clinicians and patients to make more informed decisions. As obesity continues to rise globally, embracing evidence-based, mechanism-driven therapies will be key to improving long-term metabolic health."

News18 Newsletter Handpicked stories, in your inbox A newsletter with the best of our journalism submit

About the Author Swati Chaturvedi Swati Chaturvedi is a seasoned media professional with over 13 years of experience in journalism, digital content strategy, and editorial leadership across top national media houses. An alumna of Lady... Read More

First Published: June 25, 2026, 10:55 IST

News lifestyle health-and-fitness GLP-1 Explained: How It Influences Hunger, Weight And Metabolic Health